HKEX filings. Mispriced companies. Written up when the math holds.
I have been reading annual reports for years, mostly in Hong Kong. At some point I started writing things down. Then sharing them. Trading852 is that — a public record of the situations I find interesting enough to work through in detail.
I am not a licensed financial analyst. I do not manage third-party capital. I have no position disclosures to make beyond what is stated in individual articles. What I have is time, a methodical reading habit, and a bias toward companies that are measurably cheap relative to what they own — not what the market feels about them.
Because it is one of the few markets where doing the work still gives you an edge.
Institutional coverage on mid-cap HK conglomerates is thin. The structures are complex enough that most people do not bother. And because the market has been in the news for the wrong reasons since 2021, a lot of quality businesses are priced as if the discount is permanent.
Many of those businesses generate real cash, pay dividends, hold net cash balance sheets, and have insider ownership that aligns with long-term holders. The market's narrative and the filing's reality are often two different things. I try to find the ones where the gap is measurable and the conditions for it to close are identifiable.
Every analysis starts with the chart. Then straight to the filing. I do not form a view from sell-side summaries or news headlines and then go looking for confirmation in the numbers. I go to the numbers first.
The core framework is sum-of-parts valuation: break the company into its operating divisions, value each on its own merits using observable peer multiples, add the balance sheet, subtract the debt. That gives a range for intrinsic value. Then I compare that range to the current market price.
If there is a meaningful gap, the next question is what closes it and on what timeline. Buybacks, privatisation offers, asset disposals, dividend recaps, earnings inflections — these are the catalysts I look for. A cheap company with no mechanism to close the discount is a value trap. A cheap company with a credible catalyst is a situation worth writing about.
When I find one that holds up under scrutiny, I write about it here. The analysis includes the key data, the valuation framework, the bull and bear scenarios, and the specific trigger I am watching. Nothing is hidden behind a paywall. The track record is public on the Scorecard.
This is not investment advice. I am not telling you what to buy or sell. I am sharing my research because writing forces me to think clearly — and because I would rather read research that is honest about its assumptions and its risks than analysis that pretends they do not exist.
Every analysis is a point-in-time snapshot. Markets move. Facts change. What looks like a margin of safety in April may look different in August. Read the filings yourself. Build your own model. Make your own decisions. Read the disclaimer before you act on anything here.
← Back to analyses